156 related articles for article (PubMed ID: 22878376)
1. Stopping clinical trials early for futility: retrospective analysis of several randomised clinical studies.
Jitlal M; Khan I; Lee SM; Hackshaw A
Br J Cancer; 2012 Sep; 107(6):910-7. PubMed ID: 22878376
[TBL] [Abstract][Full Text] [Related]
2. A systematic survey of randomised trials that stopped early for reasons of futility.
Walter SD; Han H; Guyatt GH; Bassler D; Bhatnagar N; Gloy V; Schandelmaier S; Briel M
BMC Med Res Methodol; 2020 Jan; 20(1):10. PubMed ID: 31948397
[TBL] [Abstract][Full Text] [Related]
3. Statistical controversies in clinical research: futility analyses in oncology-lessons on potential pitfalls from a randomized controlled trial.
Lesaffre E; Edelman MJ; Hanna NH; Park K; Thatcher N; Willemsen S; Gaschler-Markefski B; Kaiser R; Manegold C
Ann Oncol; 2017 Jul; 28(7):1419-1426. PubMed ID: 28184431
[TBL] [Abstract][Full Text] [Related]
4. An investigation of the impact of futility analysis in publicly funded trials.
Sully BG; Julious SA; Nicholl J
Trials; 2014 Feb; 15():61. PubMed ID: 24533447
[TBL] [Abstract][Full Text] [Related]
5. Comparison of futility monitoring guidelines using completed phase III oncology trials.
Zhang Q; Freidlin B; Korn EL; Halabi S; Mandrekar S; Dignam JJ
Clin Trials; 2017 Feb; 14(1):48-58. PubMed ID: 27590208
[TBL] [Abstract][Full Text] [Related]
6. Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility.
Walter SD; Han H; Briel M; Guyatt GH
Stat Med; 2017 Apr; 36(9):1506-1518. PubMed ID: 28183155
[TBL] [Abstract][Full Text] [Related]
7. A flexible futility monitoring method with time-varying conditional power boundary.
Ying Zhang ; Clarke WR
Clin Trials; 2010 Jun; 7(3):209-18. PubMed ID: 20423927
[TBL] [Abstract][Full Text] [Related]
8. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
[TBL] [Abstract][Full Text] [Related]
9. Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design.
Levin B; Thompson JL; Chakraborty B; Levy G; MacArthur R; Haley EC
Clin Trials; 2011 Aug; 8(4):398-407. PubMed ID: 21737464
[TBL] [Abstract][Full Text] [Related]
10. Optimal timing for an accelerated interim futility analysis incorporating real world data.
Haine LMF; Murray TA; Koopmeiners JS
Contemp Clin Trials; 2024 May; 140():107489. PubMed ID: 38461938
[TBL] [Abstract][Full Text] [Related]
11. When inferiority meets non-inferiority: implications for interim analyses.
Bratton DJ; Williams HC; Kahan BC; Phillips PP; Nunn AJ
Clin Trials; 2012 Oct; 9(5):605-9. PubMed ID: 22796636
[TBL] [Abstract][Full Text] [Related]
12. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
13. Pro/con clinical debate: It is acceptable to stop large multicentre randomized controlled trials at interim analysis for futility. Pro: Futility stopping can speed up the development of effective treatments.
Schoenfeld DA
Crit Care; 2005 Feb; 9(1):34-6; discussion 34-6. PubMed ID: 15693981
[TBL] [Abstract][Full Text] [Related]
14. Randomized trials stopped early for benefit: a systematic review.
Montori VM; Devereaux PJ; Adhikari NK; Burns KE; Eggert CH; Briel M; Lacchetti C; Leung TW; Darling E; Bryant DM; Bucher HC; Schünemann HJ; Meade MO; Cook DJ; Erwin PJ; Sood A; Sood R; Lo B; Thompson CA; Zhou Q; Mills E; Guyatt GH
JAMA; 2005 Nov; 294(17):2203-9. PubMed ID: 16264162
[TBL] [Abstract][Full Text] [Related]
15. Futility monitoring for randomized clinical trials with non-proportional hazards: An optimal conditional power approach.
Wang X; George SL
Clin Trials; 2023 Dec; 20(6):603-612. PubMed ID: 37366172
[TBL] [Abstract][Full Text] [Related]
16. Monitoring futility in a two-by-two factorial design: the SPS3 experience.
McClure LA; Coffey CS; Howard G
Clin Trials; 2013 Apr; 10(2):250-6. PubMed ID: 23378483
[TBL] [Abstract][Full Text] [Related]
17. Hybridization of conditional and predictive power for futility assessment in sequential clinical trials with time-to-event outcomes: a resampling approach.
Yi J; Fang L; Su Z
Contemp Clin Trials; 2012 Jan; 33(1):138-42. PubMed ID: 21983624
[TBL] [Abstract][Full Text] [Related]
18. Applying a phase II futility study design to therapeutic stroke trials.
Palesch YY; Tilley BC; Sackett DL; Johnston KC; Woolson R
Stroke; 2005 Nov; 36(11):2410-4. PubMed ID: 16224086
[TBL] [Abstract][Full Text] [Related]
19. Early stopping in clinical trials and epidemiologic studies for "futility": conditional power versus sequential analysis.
van der Tweel I; van Noord PA
J Clin Epidemiol; 2003 Jul; 56(7):610-7. PubMed ID: 12921928
[TBL] [Abstract][Full Text] [Related]
20. Information time scales for interim analyses of randomized clinical trials.
Freidlin B; Othus M; Korn EL
Clin Trials; 2016 Aug; 13(4):391-9. PubMed ID: 27136947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
